Two Sigma Investments LP acquired a new position in Novavax (NASDAQ:NVAX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 173,605 shares of the biopharmaceutical company’s stock, valued at approximately $215,000. Two Sigma Investments LP owned approximately 0.05% of Novavax as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in NVAX. Wells Fargo & Company MN grew its stake in Novavax by 30.8% in the third quarter. Wells Fargo & Company MN now owns 446,831 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 105,117 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Novavax by 6.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company’s stock valued at $1,397,000 after acquiring an additional 71,047 shares in the last quarter. Fisher Asset Management LLC bought a new stake in Novavax during the 4th quarter valued at $179,000. Aperio Group LLC boosted its position in Novavax by 121.1% during the 4th quarter. Aperio Group LLC now owns 115,323 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 63,155 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Novavax by 349.8% during the 4th quarter. Teacher Retirement System of Texas now owns 99,952 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 77,733 shares in the last quarter. 36.88% of the stock is currently owned by institutional investors.
Novavax stock opened at $1.72 on Friday. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of -3.12. The firm has a market capitalization of $709.77, a PE ratio of -2.73 and a beta of 2.38. Novavax has a 1-year low of $0.73 and a 1-year high of $2.75.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). The firm had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $7.98 million. Novavax’s quarterly revenue was up 92.6% on a year-over-year basis. During the same period last year, the firm earned ($0.21) earnings per share. equities research analysts expect that Novavax will post -0.57 EPS for the current fiscal year.
Several brokerages have issued reports on NVAX. Citigroup raised Novavax from a “neutral” rating to a “buy” rating in a research report on Thursday, March 1st. JPMorgan Chase cut Novavax from a “neutral” rating to an “underweight” rating in a research report on Monday, March 19th. Zacks Investment Research raised Novavax from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Tuesday, April 3rd. Ladenburg Thalmann raised their price objective on Novavax to $2.50 and gave the stock a “buy” rating in a research report on Thursday, January 11th. Finally, Seaport Global Securities raised Novavax from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Thursday, March 29th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.37.
ILLEGAL ACTIVITY WARNING: “Two Sigma Investments LP Acquires New Position in Novavax (NVAX)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/20/two-sigma-investments-lp-acquires-new-position-in-novavax-nvax.html.
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.